AU615637B2

AU615637B2 – Improvement of the biocompatibility of solid surfaces
– Google Patents

AU615637B2 – Improvement of the biocompatibility of solid surfaces
– Google Patents
Improvement of the biocompatibility of solid surfaces

Download PDF
Info

Publication number
AU615637B2

AU615637B2
AU82320/87A
AU8232087A
AU615637B2
AU 615637 B2
AU615637 B2
AU 615637B2
AU 82320/87 A
AU82320/87 A
AU 82320/87A
AU 8232087 A
AU8232087 A
AU 8232087A
AU 615637 B2
AU615637 B2
AU 615637B2
Authority
AU
Australia
Prior art keywords
biocompatible
agent
biocompatible agent
solid surface
molecules
Prior art date
1986-10-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU82320/87A
Other versions

AU8232087A
(en

Inventor
Patrick E. Guire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Surmodics Inc

Original Assignee
Bio Metric Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1986-10-17
Filing date
1987-10-16
Publication date
1991-10-10

1987-10-16
Application filed by Bio Metric Systems Inc
filed
Critical
Bio Metric Systems Inc

1988-05-06
Publication of AU8232087A
publication
Critical
patent/AU8232087A/en

1991-10-10
Application granted
granted
Critical

1991-10-10
Publication of AU615637B2
publication
Critical
patent/AU615637B2/en

2000-01-06
Assigned to SURMODICS, INC.
reassignment
SURMODICS, INC.
Request to Amend Deed and Register
Assignors: BIO-METRIC SYSTEMS, INC.

2007-10-16
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters

A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions

A61L29/16—Biologically active materials, e.g. therapeutic substances

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS

A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents

A61F2/0077—Special surfaces of prostheses, e.g. for improving ingrowth

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/28—Materials for coating prostheses

A61L27/34—Macromolecular materials

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

A61L27/54—Biologically active materials, e.g. therapeutic substances

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters

A61L29/08—Materials for coatings

A61L29/085—Macromolecular materials

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment

A61L33/0005—Use of materials characterised by their function or physical properties

A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials

A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials

A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines

A61L2300/254—Enzymes, proenzymes

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices

A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action

A61L2300/412—Tissue-regenerating or healing or proliferative agents

A61L2300/414—Growth factors

Abstract

The biocompatibility of biomaterials having solid surfaces is improved through coating the same with biocompatible agents. The method for modifying the solid surface to improve biocompatibility employs molecules of a biocompatible agent and a chemical linking moiety possessing a photochemically reactive group capable upon activation of covalently bonding to the solid surface and possessing a different reactive group as capable upon activation of covalently bonding to separate molecules of the biocompatible agent. One of the groups is unresponsive to activation by a stimulus to which the other group is responsive. The method comprises applying stimulus to sequentially activate the groups and covalently bind the different reactive group of the linking moiety to the molecules of the biocompatible agent and to photochemically covalently bind the linking moiety to the solid surface with a sufficient population density to enable the molecules of the biocompatible agent to effectively shield the solid surface and to provide a biocompatible surface.

Description

I AU-AI-82320/87
I
PCT JVORLD INTELLECTUAL PROPERTY ORGANIZATION 0pI INTERNATIONAL APPLICA N JIB .E N R T PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 4 (11) International Publication Number: WO 88/ 02623 A61F 2/54 Al (43) International Publication Date: 21 April 1988 (21.04,88) (21) International Application Number: PCT/US87/02675 (22) International Filing Date: 16 October 1987 (16.10.87) (81) Designated States: AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent).
(31) Priority Application Number: 920,567 (32) Priority Date: (33) Priority Country: 17 October 1986(17.10.86) Published With international s Before the expiratiorn claims and to be rep (71) Applicant: BIO-METRIC SYSTEMS, INC. [US/US]; of amendments 9932 West 74th Street, Eden Prairie, MN 55344 (US).
(72) Inventor: GUIRE, Patrick, 674L Tartan Curve, Eden Prairie, MN 55344 (US), (74) Agents: BAUMAN, Mary, P. et al,, Fredrikson Byron, 1100 International Centre, 900 2nd Avenue South, Minneapolis, MN 55402-3397 (US).
earch report.
i of the time limit for amending the ublished in the event of the receipt 2 JUN 1988
AUSTRALIAN
6 MAY 1988 PATENT OFFICE (54) Title: IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES (57) Abstract The biocompatibility of bionm’terials having solid surfaces is improved through coating the same with biocompatible agents, The method for modifying the solid surface to improve biocompatibility employs molecules of a biocompatible agent and a chemical linking moiety possessing a photochemically reactive group capable upon activation of covalently bonding to the solid surface and possessing a different reactive group as capable upon activation of covalently bonding to separate molecules of the biocompatible agent, One of the groups is unresponsive to activation by a stimulus to which the other group is responsive. The method comprises applying stimulus to sequentially activate the groups and covalently bind the different reactive group of the linking moiety to the molecules of the biocompatible agent and to photochemically cov.
alently bind the linking moiety to the solid surface with a sufficient population density to enable the molecules of the biocompatible agent to effectively shield the solid surface and to provide a biocompatible surface.
4, ML -A WV 1 8/02623 PCT/US87/02675 1 IMPROVEMENT OF THE BIOCOMPATIBILITY OF SOLID SURFACES FIELD OF INVENTION This invention relates to the field of biochemistry and particularly to the enhancement of the biocompatibility of various surfaces.
BACKGROUND OF THE INVENTION The implantation of such biomaterial articles as substitute blood vessels, synthetic and intraocular lenses, electrodes, catheters and the like in and onto the body is a rapidly developing area of medicine, A primary impediment to the long-term use of such biomaterial implantables as synthetic vascular grafts has been the lack of satisfactory graft surfaces. The uncoated surfaces of synthetic blood vessels made from plastics, for example, often stimulate rapid thrombogenic action, Various plasma proteins play a role in initiating platelet and fibrin deposition on plastic surfaces. These actions lead to vascular constriction to hinder blood flow, and the inflammatory reaction that follows can lead to the loss of function of the synthetic implantable, 1 WO 88/02623 PCT/US87/02675 -2- A “biomaterial” may be defined as a material that is substantially insoluble in body fluids and that is designed and constructed to be placed in or onto the body or to contact fluid of the body. Vascular grafts and contact lenses are examples of biomaterials.
Ideally, a biomaterial will have the following characteristics: 1. It will not induce undesirable reactions in the body such as blood clotting, tissue death, tumor formation, allergic reaction, foreign body reaction (rejection) or inflammatory reaction, 2. It will have the physical properties such as strength, elasticity, permeability and flexibility required to function as intended, 3. It can be purified, fabricated and sterilized easily.
4, It will subs~antially maintain its physical properties and function during the time that it remains implanted in or in contact with the body, whether it be an hour or a lifetime, As used herein,Athe solid surface of a biomaterial is as “biocompatible” if it is capable of functioning or existing in contact with biological fluid and/or tissue of a living organism with a net beneficial effect on the living organism.
Long term biocompatibility is desired for the purpose of reducing disturbance of the host organism, A number of approaches have been suggested to improve the biocompatibility of implantable items, One approach has been to modify the surface of a biomaterial to prevent undesirable protein adhesion by providing the biomaterial with a low polarity surface, a negatively charged surface or a surface coated with biological materials such as enzymes, endothelial WO 88/02623 PCT/US87/02675 -3cells and proteins. Solid surfaces have been coated with biochemical materials such as heparin, albumin and streptokinase to enhance thromboresistance.
Albumin in particular has been physically adsorbed onto and electrostatically and covalently bound to polymer surfaces, Munro, et, al, U.S, Patent No, 4,530,974 discloses a method of adsorbing albumin to a water-insoluble polymer such as polyurethane by covalently binding to the surface a nonionic hydrophobic aliphatic chain to which albumin will selectively bind.
Nimni et al, U.S. Patent 4,378,224 teaches a method of coating animal tissues, used to make prosthetic devices, through the formation of a three dimensional cross-linked matrix primarily composed of a calcification inhibitor, An example of an adverse reaction that is caused by the presence of a biomaterial is the deposition of protein on contact lenses, Often contact lens wearers develop an intolerance to their contact lenses with time and this intolerance may be linked to irritation and allergic responses to biochemicals (proteins, lipids, mucopolysaccharides, and others) which deposit onto the lenses while they are worn.
Current cleansing and disinfection procedures remove some of these deposits, but these procedures often leave holes and crevices in the lenses which add to the eye irritation of the wearer and serve as foci for further biochemical deposition.
Guire, US. Patent No, 3,959,078, describes the use of reagents to covalently bind an enzyme to aminoethyl cellulose or alkylamine glass. See, also: Guire, Stepwise Thermonhotochemical Cross-linking for 4 A. I I t I WO 88/02623 PCT/CS87/02675 Enzyme Stabilization and Immobilization; Enzyme Engineering 3:63-70 (1978) and Guire, Photochemical Immobilization of Enzymes and Other Biochemicals, Methods in Enzymology XLIV:280-288 (1976). These references describe a process of covalently binding an enzyme to substrates such as chemical derivatives of controlled-pore glass, cellulose, agarose and polyacrylamides by thermochemically coupling a linking reagent to the solid surface and photochemically coupling the enzyme to the linking reagent to provide a surface useful in the -erformance of in vcita diagnostic assays.
SU AkURY OF THE :NVENT:ION The invention relates to biomaterials that are provided with desired bioccmpatible surfaces, A method for modifying the solid surface of a biomaterial employs molecules of a biocompatlble aent and or mc4oem 4/y a chemical-linking moiety possessing a photochemicallV 4 reactive group capable, upon activation, of dovalently bonding to the solid surface and possessing a different reactive group that is capable, upon activation, of covalently bonding to separate mol.ecules of the biocompatible agent. One of the groups is unresnonsive to activation by a stimulus to which the other group is responsive. The method comprises applying stimulus to sequentially activate the grouns to covalently bind the different reactive group of the inking moiety to the molecules of the biocompatible agent or 4rock’e.4chi( agent and to photochemicalIly covafently bind the linking moiety to the solid surface with a sufficient population density to enable the molecules of the bioccmpatible agent to effectively shield the solid surface and to provide a biocompatible effective surface, A biocompatible “effective” surface is thus formed of a plurality of separate molecules of a biocompatible agent covalently linked, through a linking C;s “I “1 -00 WO 88102623 PCT/US87/02675 5 moiety, to the solid surface of a biomaterial to provide that surface with substantially the same biocompatible characteristics as are possessed by the biocompatible agent. The effective surface formed by the molecules of the biocompatible agent need not cover the entire surface of a biomaterial. It may cover the surface in spots. For example, spots along the surface of vascular grafts may be covered by a cell attachment factor such as fibronectin. The biocompatible effective surface formed at those spots then act as foci for attachment of cells to the modified surface, The different reactive group of the linking moiety desirably is a thermochemical group or a photochemical group that is unresponsive to the stimulus to or erMeMawe which the first mentioned photochemically reactive group responds and to which molecules of the biocompatible agent will covalently bind, In another embodiment of the invention there is provided a device having a biocompatible effective surface formed of separate molecules of a biocompatible agent covalently linked by a chemical linking moiety residue to the solid surface of the device, The chemical link’g moiety esidue includes a residue of a photochemicallyreactive group covalently bonded to the solid surface, and, covalently bonded to molecules of the biocompatible agent, the residue of a different reactive group, one of the reactive groups being unresponsive to a stimulus to which the other reactive group responds. The individual molecules of the biocompatible agent are attached through the linking moiety residue to the solid surface sufficiently proximate to one another as t, cause said molecules to effectively shield the solid surface and to provide a biocompatible effective surface.
4a
V
P
V”
L-L I i- L WO 88/02623 PCT/US87/02675 6 The biocompatible agent is chosen to enhance the function of a particular device. For example, the function of contact lenses may be enhanced by attaching molecules of polyethylene glycol to the lens surfaces to diminish the deposition of proteins on these surfaces. As another example, a cell attachment factor such as fibronectin or laminin may be bonded to a device having a polyvinyl chloride surface to increase cell attachment to che device. This is desirable in the case of implantables such as catheters and substitute blood vessels.
Yet another embodiment of the invention involves a method for modifying the solid surface of a biomaterial, the method employing molecules of a biocompatible agent joined to one another to form a biocompatible film, and a chemical linking moiety capable of linking the film to the solid surface of the biomaterial. The chemical linking moiety includes a photochemically~reactive group capable upon activation of covalently bonding to the solid surface, and the residue of a reactive group covalently bonded to the film to the residue of the biocompatible agent molecules making up the film). One of the reactive groups is unresponsive to a stimulus to which the other reactive group responds. The method comprises activating the photochemically reactive group with a stimulus to covalently bind the biocompatible molecules. By “joined” in this context, reference is made not only to covalent bonding of adjacent biocompatible agent molecules but also to interactions caused by such forces as hydrogen bonding, ionic bonding, bonding through Van der Waals forces, and the like, The biocompatible agent having molecules joined to one another to form a film may comprise molecules of one agent or it may comprise molecules of two or more agents such as hepazin and albumin.
k: WO 88/02623 PCT/US87/02675 -7- DESCRIPTION OF THE PREFERRED EMBODIMENTS The solid surface that is rendered biocompatible in accordance with the invention desirably is of a synthetic or natural material that is insoluble in physiological fluids. The surface may be one or more surfaces of devices intended to function in contact with tissue and/or fluids of living organisms. The solid surface of the device may be any suitable metal such as polished titaium or stainless steel or a polymer such as polyurethane, polyvinylpyrrolidone, silicone elastomers, polyethylene, polytetrafluoroethylene, poly-(p-phenyleneterephthalamide), polyvinyl chloride, polypropylene, polyolefins, polyesters, polyacrylates (including polymethacrylates); minerals or ceramics such as hydroxyapitite; human tissue such as bone, skin and teeth; organic materials such as wood, cellulose and compressed carbon; and other-natUral and synthetic materials such as glass, rubber, wood and th, like. Examples of devices which may be provided with biocompatible surfaces in accordance with this invention include vascular graft tubing, dialysis tubing or membrane, blood oxygenator tubing or membrane, ultrafiltration membrane, intra-aortic balloon, blood bag, catheter, suture, soft or hard tissue prosthesis, synthetic prosthesis, artificial organs, and lenses for the eye such as contact and intraocular lenses, The solid surface is desirably thermachemically unreactive “Thermochemically unreactive” means that the surface is free of any surface treatment designed to increase the ability of the surface to thermochemically react, Examples of thermochemically unreactive surfaces include polytetrafluroethylene, polyethylene, polypropylene, polyvinyl chloride, polyvinylpyrrolidone, silicone elastomers, stainless steel and titanium,
,I
WO 88/02623 PCT/USS7/02675 8 Molecules of a biocompatible agent are attached to the surfaces of biomaterials to improve biocompatibility. The biocompatible agent e a growt:h factor such as endothelial cell growth factor, epitnial cell growth factor, osteoblast growth factor, fibroblast growth factor, platelet derived growth factor, neural growth factor, or angiogenin growth factor; an antimicrobial agent such as lysosyme or penicillin; an antithrombogenic agent such as heparin, albumin, streptokinase, tissue plasminogin activator (TPA) or urokinase; a thrombogenic agent such as collagen or a hydrophilic polymer such as polyethylene glycol, hyluronic acid, chitosan or methyl cellulose, and other proteins, carbohydrates and fatty acids.
The biocompatible agent may comprise molecules of one of the above listed agents or it may comprise molecules of two or more agents., For example, the biocompatible agent may comprise molecules of both albumin arn heparin.
In one embodiment the molecules of a biocompatible material are joined to one another to form a film that is attached to a solid surface by a linking moiety. The biocompatible agent desirably may be hyaluronic acid or albumin. A biocompatible device having a film attached may be an artificial hip joint coated with a film of hyaluronic acid, The chemical linking moiety preferably has the formula A-X-B in which A represents a photochemically reactive group capable in response to specific activation of bonding covalently to a solid surface; B represents a different reactive group capable desirably in response to specific activation to which group A is unresponsive, of forming a covalent bond to a biocompatible aqsen and X represents a relatively inert, noninterfering skeletal moiety joining groups and S WO88/02623 PCT/US87/02675 9 that is resistant to cleavage in aqueous physiological fluid, The physiological fluid referred to is such fluid with which X will come in contact.
X is preferably a C 1
-C
10 alkyl group such as polymethylene, a carbohydrate such as polymethylol, a polyoxyethylene, such as polyethylene glycol or a polypeptide such as polylysine.
The reactive group B is a group that upon suitable activation covalently bonds to proteinaceous or other biocompatible agents, Such groups are typified by thermochemical groups and photochemical groups, as described and exemplified in Guire, U.S. Patent 3,959,078, the teachings of which are incorporated herein by reference.
The photochemically reactive groups (the covalent bonding of which is activated by actinic radiation) may be typified by aryl, alkyl and acyl azides, oxazidines, isocyanates (nitrene generators), alkyl and 2-ketodiazo derivatives and diazirines (carbene generators), aromatic ketones (triplet oxygen lenerators), aromatic diazonium derivatives and numerous classes of carbonium ion and radical generators, Reference is made to Frederick J, Darfler and Andrew Tometsko, chapter 2 of Chemistry and Biochemistry of Amino Acids, Peptides and Proteins (Boris Weinstein, ed) vol 5, Mtarcel Dekker, Inc, Sew York, 1978, for further description of photochemically reactive groups. Azidonitrophenyls, fluoroazido nitrobenzenes, and aromatic ketones form a preferred group due to their stability to chemical reaction conditions in the dark and their susceptibility to activation by light of wave lengths harmless to most biomaterials, to form short-lived reactive WO 88/02623 PCT/US87/02675 intermediates capable of forming~covalent bonds in useful yield with most sites on the biomaterial.
Nitrophenylazide derivatives (shown as including the X group) appropriate for use as photochemically reactive groups for the most part can be derived from fluoro-2-nitro-4-azidobenzene, and include 4-az ido-2-nitrophenyl (ANP)-4–amino–butyryl, ANP-6-aminocaproyl, ANP-11-aminoundecanoyl, ANPglycyl, ANP-aminopropyl, ANP-mercaptoethylamino, ANP-diaminohexyl, ANP-diaminopropyl, and ANPpolyethylene glycol, ANP-6-aminocaproyl, ANP-11aminoundecanoyl, and ANP-polyethylene glycol are preferred, Aromatic ketones preferred for use as photochenically reactive groups include benzyllbenzoy.
and nitrobenzylbenzoyl, Thermochemical reactive groups (that are activated by heat energy) are typified by and include nitrophenylhal.ides, aJlkylaminoi alkylcarboxyl, a1ky),thiol, alkylaldehyde, akyirnethylimidate, alkylisocyanate, alkylisothiocyanate and alkylhalide groups.
(4roups appropr’iate for use as thetrnochemically reactve groups Include carboxyl groups, hydro.yl groups, primary amino groups, thio groups, maleimides and halide groups, N-oxysuccinimide carboxylic esters of such groups as 6-amino heoanoic acid and amino undecanic acid, alkylthiol groups such as mercaptosuccinic anhydride and beta-mercaptopropionic acid, homocysteinethiolactones, and poiyetheyiene glycol derivatives are preferred, 4 The devices of this invention have biocomatible solid surfaces that include molecules of a biocompatible agent and a chemical linking moiety rosi-, due. The chemical linking moiety residue possesses a WO 88/ 02623 PCT/US87/02675 residue of a photochemically reactive group bonded to the solid surface and possesses a residue of a different reactive group covalently bonded to the biocompatible agent, The residue of the photochemically reactive group is that portion of a photoreactive group (described above) represented by in the general formula, that remains after a covalent bond h~as formed, When the photoreactive group is ANP and the solid substrate is polyethylene, the residue is a carbon-nitrogen bond. A nitrene formed when AINP is light-activated, reacts with a carbon of the polyethylene to for’m a covalent bond. When the photoreactive group is BBA and the solid substrate is polyethylene.
the residue is a carbon-carbon bond. rdhen BBA i stimulated by light, the carbon joining the two nhenyl groups is activa~ted to a triplet state -,ausinq a carbon-carboz% bond to form between the polyretheylene and the SBA and to form an hydro.4-yl grolup, Whoti the different reactiveQ group 1) is I’1Q$ the residue is the carboxyl carbon oe that group bonded to an _-%ygon or nitrogen group of a biocompati)ie agYn suc h as elbronectia, As enzymes, dell attachment factors and cortain other substances that may be employed 48 biocompatib)’ agejits aro somewhat seasiti-oe to high tpauei is desired that the different reative group on the moiety employed in the present i ti: 11- ]c activated by (that is, ut~lecgo covalent boniding in, respon~e to) easily applied aAd aonharmfn,.l stmull such as moderate heat (ecj,, body temperature we bolow) and light,, a.eactive groups that are c epn4v to the stimuluis to which the potochemica.lly re activo) WO 88/02623 PCT/US87/02675 12 group responds may be groups that react to changes in pH, or to the addition of another chemical species and the like, The chemical linking moieti, desirably covalently bond to the surface in such population to enable the molecules of biocompatible agent moieties to shield the solid surface and to provide a biocompatible effective surface. The density of bound chemical moieties necessary to provide an effective surface varies with the particular biocompatible agent used, The invention may be better understood by reference to the following non-limiting examples, Table 1 is a list of abbreviations of terms used in the following descriptions, w A W6\rd88/o2623 PCT/USS7/0275 TABLE 1: Abbreviation
EGF
PEG
PVC
PE
PP
PTFE
FNAB
ANP
KOH
TLC
NOS
EAC(A)
AUD(A)
BBA
DMSO
DMF
EDC
LIST OF ABBREVIATIONS Full Name Endothelial growth factor Polyethylene glycol Polyvinyl chloride Polyethylene Polypropylene Polytetrafluoroethylene Fluoronitroazidobenzene 4-azido-2-nitrophenyl Potassium hydroxide Thin layer chromatography N-oxysuccinimide Epsilon amino -aproiz acid Amino undecanoic acid Benzoyl benzoic acid Dimethy. sulfoxide Dimdthylformamide 1-ethyl-3-(3,-dimethylaminopropyl) carbodimide Polyethylene glycol, molecular weight 1000 Polyethylene glycol molecular weight 4000 Phosphate buffered saline Fibronectin Collagen Nitl:obenzoylbenzoic acid N-2-hydroxvyethylpiperazine NW-2-ethane sulfonic acid Human serum albumin Human gamma globulin Lyzosyme millimole PEG-l000 PEG-4000
PBS
FN
COL
nBBA
HEPES
HSA
HGG
LYZ
mmol1 e
IVI
V:
WO 88/02623 PCT/US87/02675 14 TABLE 1 Continued; LIST OF ABBREVIATIONS Abbreviation Full Name ml milliliter MW app Approximate molecular weight mg milligram M Molar pmole picamole ng nanogram ug microgram ID Inner diameter Example 1 Endothelial Cell Attachment/Growth Plastic Surfaces. Various cell factors were coupled to polymeric surfaces tested in vitro to determine the effect of these factors upon cell attachment and overgrowth. The polymeric surfaces included polyvinyl chloride (PVC), polyethylene (PE), polypropylene (PP) and polytetrafluoroethylene (PTFE) GORE-TEX (6mm reinforced expanded PTFE, a trademarked product of W. L. Gore and Associates, Inc.). Commercial tubing tested included polyester (Dacron, D, 6mm straight knitted dacron velour, a trademarked product of Dupont), silicone elastomer, (Silastic R, S, 0.03 tubing, a trademarked product of Dow Corning) and polyurethane. Polystyrene plates were used as controls.
2. Preparation of the Chemical Linking Moiety.
The chemical linking moiety used in these examples were the N-oxysuccinimide (NOS) esters of 4-azido-2-nitrophenyl epsilon amino caproic acid (ANP-EACA), 4-azido-2-nitro-phenyl amino undecancic acid (ANP-AUDA) and benzoylbenzoic acid (BBA), S i WO 88/02623 PCT/US87/02675 15 ANP-EAC-NOS and ANP-AUD-NOS were prepared by the method described in P. Guire, D. Fliger and J, Hodgson, “Photochemical Coupling of Enzymes to Mammalian Cells”, Pharmacological Research Communications, Vol. 9, pp 131-141 (1977), incorporated herein by reference. Briefly, fluoro-2-nitro- 4-azido benzene was reacted with either epsilon amino caproic acid or amino undecanoic acid to substitute the relatively poorly reactive fluoride with an amino alkyl carboxy group, The carboxy group was then esterified, by carbodiimide activation with N-hydroxy succinimide to yield the N-oxysuccinimide carboxylic ester. The NOS ester of benzoylbenzoic acid was prepared by esterifying the carboxy group by carbodiimide activation with N-hydroxy succinimide, When ANP-EAC-NOS or ANP-AUD-NOS is the chemical linking moiety used, the ANP group is the photochemically reactive group represented by the letter in the A-X-B general formula discussed above, The NOS group is the different reactive group represented by the letter in the formula. The EAC or AUD group acts as the spacer between the two reactive groups and is represented by the X in the general formula, When BBA-NOS is the chemical linking moiety, the benzoylbenzoic group is the photochemically reactive group represented by the in the general formula and the NOS group is the different reactive group represented by the letter The ‘group represented by X is the carbon connecting the two reactive groups.
3. Covalent Bonding of Growth Factors to the Chemical Linking Moieties, The biocompatible agents fibronectin, laminin, collagen, endothelial growth WO 88/02623 PCT/US87/02675 -16factor, and human serum albumin were tested for their abilities to promote endothelial cell attachment and overgrowth on synthetic biomaterials. These agents were coupled to the N-oxysuccinimide (NOS) esters of 4-azi—2-nitrophenyl epsilon amino caproic acid (ANP-EACA), 4-azido-2-nitrophenyl-undecanoic amino acid (ANP-AUDA) or benzoylbenzoic acid (BBA) as follows. As used herein “photolabeled” refers to a biocompatible agent that has been coupled to a jhemical linking moiety by the different reactive group and that has a photochemically reactive group.
A, Covalent Binding of Fibronectin and Laminin to the Linking Moiety. Human fibronectin (University of Wisconsin Medical School) and mouse laminin (obtained from Bethesda Research Lab.) were separately dissolved at 1 mg/ml concentrations in 0.1M borate, pH 9.0. A solution of ANP-EAC-NOS in dry dimethylformamide ANP-AUD-NQS in dry DMF, or BBA-NOS in dry dioxane was slowly added to the fibronectin or laminin solution in equamolar amounts to the concentration of protein epsilon amino groups (lysine residues) by syringe drive at 4 9 C in the dark over 16 hours, Then the mixture was stirred 4 hours in the cold. The fibronectin or laminin solution was centrifuged to remove insoluble material then applied to a Sephadex G-75 column to remove uncoupled photoreagent, The factions were monitored at 260nm and 462nm to assess the photogroup/protein ratios, B, Covalent Binding of EGF, Collagen, and HSA to Chemical Linking Moieties. Human placenta Type IV collagen (Sigma Pharmaceutical), endothelial growth factor (Sigma Pharmaceutical), and human serum albumin (Sigma Pharmaceutical) were separately dissolved at 2 mg/ml concentrations in 0.1M borate, pH solution of ANP-EAC-NOS in DMF, ANP-AUD-NOS in A
I
WO 88/02623 PCT/US87/02675 17 DMF or BBA-NOS in dioxane was slowly added to the solution containing the biocompatible agent in molar amounts to the concentration of epsilon amino groups (lysine) residues by syringe drive at 4 0 C in the dark over 16 hours. Then the solution was dialyzed against 4 1000ml changes of phosphate buffered saline (PBS) and centrifuged to remove insoluble material. The product was analyzed at 260nm, 280nm and 462nm to assess the photogroup/protein ratios.
4. Covalently Binding the Biocompatible Agents to Plastic Surfaces, Various sheets, tubes and flat pieces of polyethylene, polyvinyl chloride, polypropylene, polyurethane, Dacron R (velour), SilasticR (medical grade), and polytetrafluroethylene above were used. A 0.05ml aliquot of solutions containing 0 to 500 ug/ml of photolabeled biocompatible agent was added to each 0.5 cm 2 section of plastic surface.
I The solution was allowed to adsorb onto each piece for 3 hours at room temperature in the dark, The excess liquid was removed and the biocompatible agents were covalently linked to the surfaces by photolysis for 12 hours at the appropriate wavelength (Tungsten “spotlite” for ANP and long wavelength UV for BBA).
After photolysis, the specimens were washed with a 4 second stream of PBS to remove non-covalently linked molecules of photolabeled biocompatible agent. The pieces were then placed in tissue culture to assess the endothelial cell reaction to the cell factors as follows.
In Vitro Tests Performed with Modified Surfaces.
A. Radio-labeled biocompatible agents.
Radiolabeled Hi biocompatible agents were photolabeled as described above and photocoupled to plastic surfaces, The plastics surfaces were extensively washed with PBS, then dissolved in organic IC-~ L ii J. -i -i C WO 88/02623 PCT/US87/02675 18 solvent, and counted by liquid scintillation spectrometry. Some representative results are given in the Table 2.
Table 2. Sample results of amounts of growth factors photocoupled to various materials Photolabeled Ng Growth Biocompatible Solid Factor Ng Growth Factor Coupling Agent Surface Applied/cm- Photocoupled/cnu Efficiency ANP-EAC-FN PVC 843.04 677.6 80.4% Polyurethane 843.04 823.04 97.6% BBA-FN PVC 3564.0 1091.2 30.62% Polyurethane 3564.0 2622.4 73.58% ANF-EAC-COL PVC 2675.2 374 14.0% Polyurethane 2675.2 2173.6 81.26% BBA-COL PVC 1105 2 197.56 17.9% Polyurethane 1105.2 920.3 83.3% As these results show the photolabeled biocompatible agents covalently coupled to these surfaces, B. Attachment of Bovine Endothelial Cells to Modified Plastic Surfaces. Bovine endothelial cells were collected from fetal animals 8-24′ in length. Cornea, aorta and umbilical endothelial cells were harvested aseptically. Cells were grown in a 5% CO 2 incubator at 37 0 °C in a known high glucose cell growth medium such as Dulbecco’s modified Eagle’s medium (described in R. Dulbecco and G. Freeman, Virology, Vol, 8:396 (1959) and J, D. Smith, G.
Freeman, M. Vogt and R. Dulbecco, Virology, Vol.
12:185-196 (1960)) with 25mmole HEPES buffer, bovine calf serum, and 2.5 micrograms amphotericin B/ml (the “growth media”), Once the plates, tubes or sheets were prepared; cell cultures were prepared from primary cell lines, The cells were detached from the WO 88/02623 PCT/US87/0267′ 19 cell lines with a 0.25% solution of trypsin and resuspended in the growth media. Cells were then counted using a trypan blue solution and a hemocytometer. Various concentrations of cells were layered on the prepared materials, Cell attachment was monitored for various time periods from 5 minutes to 14 days. Attachments were determined by at least two methods, In one, sample materials were removed from culture media and washed 2 times with sterile saline, Cell stains were then applied and total cells on the surface were counted. A second method was to trypsinize the cells off the surface with a trypsin solution and count using the trypan blue method, Representive results of the attachment and outgrowth of endothelial cells on precoated polyvinyl chloride plastic pieces are reported in Table 3. The number of viable cells attached to each piece were determined by trypan blue staining procedures.
Table 3. Cell attachment determinations and outgrowth of endothelial cells on the treated polyvinyl chloride surface.
Biocompatible agent and chemical-linking Ng growth 3-day cell 7-day cell moiety factor/c counts* counts 7-day outgrowth* ANP-EAC-FN 677.6 2610(2+-3+) 3539(2+-3+) 1.5-1.75mm(2+) BBA-FN 1091.2 868(1+-2+) 14500(2+) 3.75-4.25mm(2+-3+) ANP-EAC-COL 374.0 14500(3+-4+) 15833(2+-3+) 1.0-3.0mm(3+) BBA-COL 197.6 5749(2+) 21500(3+) 2.5-4.0mm(3+) Control PVC 0 5-2.0mm(3+) C. Attachment of Human Umbilical Endothelial Cells, Primary human endothelial cells were harvested WO 88/02623 PCT/US87/0267:5 20 from fresh (less than 4 days old) human umbilical cords. Cords were rinsed with 20 mls-cord buffer (0.144M NaCI, 0,004M KCI and 0,001M P0 4 twice to remove blood and clots. Collagenase was pushed into the cord and left for 20 minutes at room temperature, Using 10 ml of warm cord buffer, the collengenase and detached cells were flushed into tubes. The suspension in the tubes were combined and centrifuged at 1500 rpm for 5-10 minutes. The supernatant was poured off and the cells resuspended in 10 ml of cord buffer. Following the second centrifugation, the cells were resuspended in cord buffer and plated into tissue culture disks, All cells were incubated in 37 0 C incubator with 5% CO 2 Cells were radiolabeled using 51Cr in cord media without calf seruwt, Labeled cells were then used for cell attachment studies, Plates, sheets, and tubes of the plastics described above were prepared as recorded above, The cells were trypsinized and counted with the trypan blue method, Cells were allowed to adhere to the prepared plastic for three hours to seven days, Cells were rinsed off and the total number of any results attached cells were compared to the number of non-attached cells, Representative results appear in Table 3 above, D. Outgrowth Measurement using Endothelial Cells, The following techniques were used to monitor the outgrowth of cells from a point of origin as the cells grow to cover the surfaces of the plastics listed above modified av iollows. Solutions of biocompatible agents conmtaining from 0 to 500 micrograms of cell factors weve coated onto surfaces from 1
L.
WO 88/02623 PCT/US87/02675 21 to 6 cm long to establish a gradient, Cells were not detached from the tissue with trvpsin or any proteinase. The tissue was placed on a point of origin at the low end of the gradient and marked. The tissue was allowed to sit for 15 minutes at room temperature, Growth media was added to give a moist coating over the plastic. All protocols were carried out using aseptic conditions. Plates were then incubated at 37°C in a 5% CO 2 incubator, Outgrowth was measurdrl daily for up to two weeks or until the length of plastic was completely covered. Outgrowth on the treated surfaces was compared to nontreated control surfaces as reported in Table 3 above. All materials were rinsed and stained for permanent scanning electron microscopy, These results demonstrated that the covalent attachment of the growth factors f’,bronectin (FN) and collagen (COL) to ,the plastic surface improved the biqcompatibility of the plastic with bovine endothelial cells, The cells preferentially attached to the modified surfaces versus control surfaces as is indicated by the distance they grew out over the plastic surface.
6. In Vivo Studies.
Two conditioned dogs were obtained for this study. Pieces of GORE-TEX (reinforced expanded polytetrafluroethylene, a trademarked product of W, L, Core and Associates, Inc.) were precoated with FN, AITP-EAC-FN (adsorbed and photocoupled), ANP-EAC-FN (adsorbed only) and a PBS-control. The testing was a blind study. The grafts were labeled by lettering; however, the surgical team did not kn,.w which grafts had modified surfaces and which were controls. Each dog received two 6mm x 5cm pieces of GORE-TEX implanted in the left and right iliac artery. The WO 88/02623 PCT/US87/02675 22 grafts were left in the dogs for one month (30 days), The dogs were given the anti-inflammatory drugs Persontine and Aspirin to mimic human implant procedures, Both control grafts (PBS and FN) were patent and had sufficient caliber, The anastomatic lines were intact and the inner surfaces were smooth, Endothelialization was incomplete with the control grafts. There appeared to be no evidence of significant thrombosis. Both grafts to which ANP-EAC-FN was bound (photocoupled and adsorbed only) were free of thrombosis formation. Endothelialization was complete giving the inner surfaces of the grafts a smooth, shiny appearance.
Example 2 Modification of the Surfaces of Contact Lenses and Introcular Lens Implants S. The experiments described in this example involved preparations of hydrophilic polymers (a biocompatible agent) bound to a chemical linking moiety, photocoupling the moieties to contact lens surfaces, and measuring the in vitro protein deposition from artificial tear solutions onto these lenses in comparison to non-treated lenses, Experiments to study the compatibility of the biocompatible agents in vitro with corneal pieces and in vivo in rabbit eyes were conducted to assure that there were not toxic or irritant reactions to the resulting lenses, 1. Binding Biocompatible Agents to the Chemical Linking Moiety, A. Preparation of Photolabeled Polyethylene Glycols, Polyethylene glycols of molecular weights 1000 (PEG-1000) and 4000 (PEG-4000) were labeled with fluoronitrozidobehzene (FNAB) by modification of the phase transfer method of “Kimura,
I*
1A WO 88/02623 PCT/US87/02675 23 and S, Regen, Journal of Organic Chemistry 48; 195 (1983) the teachings of which are incorporated by reference herein, Briefly, the phase-transfer synthesis of 4-azido-2-nitrophenyl polyethylene glycol (ANP-PEG) involved the mixture of 60% aqueous potassium hydroxide (“KOH”)/toluene with FNAB and PEG, followed by extraction and thin layer chromatographic (TLC) purification as described below, ANP-PEG-1000. ANP-PEG-1000 was prepared by adding 0.05 mmole PEG-1000O to 5 mis 60% KOH and mmole FNAB to 10 ml toluene. This reaction mixture was rapidly stirred at room temperature for 16 hours, The product was isolated from the organic layer, TLC in 85/15/1/1 chloroform/methanol/H 2 0/acetic acid or ammonium hydroxide separated mono-and di-substituted derivatives of ANMFG-1000 from unlabeled PEG. The band corresponding to ANP-PG-1000 (lower R value) was extracted from silica gel with TLC solvent and azeotrophed to remove residual acid or base, The final product was soluble in water and resulted in the conversion of 30-40% Qf the PEG starting material to A\P-PEG-O0 product.
ANP-PEG-4000. The ANP-PEG4000O was prepar@d by the same procedure as that described above except that the treaction mixture was rapidly stirred at 501C to ensure all reagents remained in solution during the course of the reaction. The yield of AN?-PG-400-O0 was B. Preparation of Photolabeled Jeffamines,. Polyoypropylenpolyamines and polyoxyethylenepolyamines (referred to as “Jeffamines”, a trademark of Jefferson ChQmical Co., Inc.) WO 88/02623 PCT/US87/02675 24 were photolabeled by coupling the N-ocySuccinimide esters of ANP-EACA, BBA and nBBA to the polymers. These NOS-derivatives were added in amounts to 1X Jeffamine in very dry (high purity) solvents (ANP-EAC-NOS in dry tetrahydrofuran, BBA-NOS in dry dioxane or dimethylformamide and nitro EBA-NOS in dry dioxane or dimethylformamide). After 16 hours of reaction at room temperature in the dar, the products were isolated by TLC in 85/15/1/1/ chloroform/methanol/H. 0/acetlc acid, Monosubstituted Jeffamine derivatives were extracted with the TLC solvent and azeotrophed with water to remove the residual acetic acid, The water-soluble products ANP-EAC-Jeff amine, 5A-Jef famine, and nBBA-Jeff amine were isolated in 1O0 and 12% yields, respectively.
C, Preparation of ANP-Eyaluronic Acid.
The terminal sugar of human placental hyaluronic acid (MW 100-13,o00) wa activated by the periodate app procedure described in E, Junowicz and SE, Charm, “The Derivatization of Oxidized Polysaccaridos for Vrotein :mmobilization and Affinity Chromatoqtaphy, Biachimica et Biohysica Acta. Vol. 42$ l 157-1.65 (1976) and incorporatjod hqrein by refemece. This procedure entiailod adding sodium or pota.siu perlodate to a solutior of ‘yr hyanuJanio acid thuis actvating -he terminal sugat:. The hy iuronlc aed was addod to a 1-0-fold excess of dfBPe o and allowed to react 4 hours at room temperatura. The liniKagLbS” were stabilized by reduction with sodium cyanoborohydride, ollowod by exhaustive dial;als to remove most of the oxoess Tefeamine,, A 10-told molar emceGo of AP-EA,%C– in DME was added to the ToffaminehyalUronate in 0,1 M carbonate, pH 9,0, by syr’Ali w- 88/02623 PCT/US87/02675 25 drive. This addition required 16 houtz an was conducted at room temperature in the da.rk, Th4 excess ANP-EAC-NOS and ANP-EAC-Jeffamine was remnQv’ed by gel filtration chromatography, The intetity of thez azide group, which is required for photocoupling of the moiety to the contact lens polymer backbone, was analyzed by infrared spectroscopy to detect the ANP group, a polyethylene glycol assay to detect the Jeffamine spacer, and a modified carbazole assay described in T, Bitter and H, Muir, Analytical Biochemistry Vol. 4: 330-334 (1962) and incorporated herein by reference to determine the uronic acid content of the derivative.
The polyethylene glycol assay was developed using the Dragendorff reagent (tetraiodobismuthic acid-barium chloride) A 5-mi portion of stock reagent (425-mg bismuth nitrate, 10-gm potassium fodide in acetic acid and water) was added to barium chloride in water and a background reading at 516+n was noted, Then 0.1-mi of the sample was added and the contents mixed by inversion of the cavette. A reading was taken at 516-am after 1 minute of incubation. The values were compared to a standard oiurvel The carbazole assay was performed as folows, A 3.0 ml portion of sulfuric acid reagent (0.025M sodium tetraborate-l0 H 0 in sulfuric acid) was cooled to -70VC, A 0.,5 ml portion of sample was layered onto the acid and the mixture was stirred min.) until it reached room temperature. The tubes were heated at !004C, (lQ min,), a 0,1 ml aliquot of oarbazole reagent (0,125% carbazole in absolute ethanol) was added, the tube contents were mixed (S min.), hoated at 100 0 C. (15 min.), then cooled to room O 88/01623 PCT/CS17/02675 i
I
Ijy i r~ WO 88/02623 PCT/US87/02675 26 temperature in an ice bath. The samples were analyzed spectrophotometrically at 530 nm against a sulfuric acid reagent blank. The results were compared to a standard curve constructed with 4-40 ug/ml glucuronolactone standards, The assay was sensitive to detecting 20 pmole of hyaluronic acid, The fractions containing one ANP, one Jeffamine and one hyaluronate molecule were pooled and used as a biocompatible agent, D. Prearation of Photolabeled Hyaluronic Acid, Methyl Cellulose and Chondroitin Sulfate, ANP-EAC-Jeffamine, BBA-Jeffamine and nitro-BBA-Jeffamine were linked to the carboxyl groups of uronic acid residues of hyaluronic acid and chondroitin sulfate by a carbodiimide procedure as follws. A 5 molar excess of photolabeled Jeffamine and I-ethyl -3- (3-dimethylaminopropyl) carbodiinide with HCi was mixed with the polysaccharido polyrer in water adjusted to pH 4.5 ith 0,N HC1, The mixture was allowed to react at room temperature in the dark for 24 hours, The product was purifiE, by gel filtration chromatography then analysed for photugroup and carbohydrate content as described above, E Preparation of Ph;olabeled Collaqn, Human placenta Type IV collagen (available from Sigma Pharmacueticals) was dissolved at a 1 mg/ml concentration In 0o,.M borate, pH 9,0, ANP-EAC-NOS in DMF, BBA-sulfa-NOS in dioxane or nitro BBA-OS in dioxane was slowly added to the collagen solution in a Sox molar excess by syringe drive at 4 0 C in the dark over 16 hours, After the addition was complete, the mixture was stirred 4 hours in the cold, The collagen product was dialyzed against 4 changes of PBS then centrifuged to remove insoluble material The WO 88/0 2623 PCT/US87/02675 27 supernatant was measured spectrophotometrically at 260 nm, 280 nm and 462 nm to assess the photogroup/protein ratio, F. Preparation of Photolabeled Proteinases. ANP-EAC-NOS, BBA-NOS and nBBA-NOS photogroup dissolved in organic solvent at 25 mg/ml concentrations, were added in 50 molar excess to papain (papaya, MW 23,426) by syringe drive at 4°C in the dark over ‘6 hours, After addition of the photogroup h ‘mpleted, the mixture was stirred an additional 4 then dialyzed in PDS to remove uncoupled phtr, After dialysis, the product was centrifuged to remove insoluble material, The supernatant was measured spectrophotometrically at 260 nm, 21z0 nm, and 462 nm to estimate the photogroup/ *protein ratio, Photocoupling Biocbmpatible Agents to L e ns Surfaces. The photolabeled biocompatibles agents obtained above were added to the contact lens materials described in Table 4 at a concentration of 250-1000 pmole agent/contact lens, The solution was allowed to adsorb onto the contact lenses at room temperature in the dark for 3 hours, The photolabeled agents were then covalently linked to the plastic by photolysis for 12 hours at the appropriate wave length (450 nm for ANP and 320 nm for BBA and nBBA derivatives), After photolysis, the contact lenses were washed with ml of normal saline (0,85% NaCl) to remove noncovalently linked groups, Radiolabeled groups may be coupled to the lens materials, and the lens pieces treated with tetrahydrofuran followed by DMSO to release the radiolabel from the solid surface,. Scintillation fluor is then added and the amount of biocompatible agent/cm 2 WO 88/02623 PCT/US87/02675 28 determined by liquid scintillation spectroscopy.
Representative results -re shown in Table 4.
Table 4. Load Densities of Biocompatible Agents on Various Contact Lens Materials Biocompatible Contact Lens Agent Material *pmole/cm.l Coupling ng/cm- Efficiency ANP-1000 ANP-4000 Polyvinyl chloride Sofspin (polymacon) Permaflex Vistamarec Lidofilcon Silicone **Polymacon Button Sofspin (polymacon) Permaflex Silicone **Polymacon Buttons 19.96 33.45 33.97 34.26 63.12 33.97 2408.60 27.06 42.86 170.60 1374.00 23.20 13. L4 8.21 95.61 3738.00 19.96 33.45 33.97 34.26 63.12 33.97 2408.60 108,24 171.44 682.40 6296.00 46.40 26.28 16.42 191.22 7476.00 22. 86% 12.95% 12.90% 13.20% 24.30% 4.80% 38.23% 10.50% 16.50% 22.70% 26.60% 5.10% 3.20% 13.50% 56.45% nitro BBA- Polyvinyl Chloride 2000 Sofspin Permaflex Silicone **PoLyma.on Buttons BBA-2000 Silicone **Polymacon Buttons 113.20 226.40 15.60% 4035,10 8070.20 64.30% 25.,00 25.00 7.00% 130.95 130.95 7.90% ANP-Hyal- Silicone uronic acid **Polymacon Buttons Values were averaged from replicates of 10 Folymacon loads are based on total volume, cm 3 t rather than sutrface area.
Sofspin contacts are made of polymacon (polymethacrylate) with about 38.6% water and are a trademarked product of Bausch Lomb, Inc.
Permaflex contacts are made of polymetbacrylate with about 74% water and are a trademarked product of Coopervision, Inc.
Vistamarc contacts are made of polymethacrylate with about 58% water and are a trademarked product of Johnson Johnson.
WO 88/02623 PCT/US87/02675 29 Lidofilcon contacts are made of polymethacrylate with about 70% water and are a product of Bausch Lomb, Inc.
The values in Table 4 are expressed as pmole biocompatible agent per square centimeter surface area or ng/cm 2 The coupling efficiencies were based upon addition of 260 pmole/cm 2 biocompatible agent/contact lens materials, 710 pmole/cm 2 biocompatible agent/ silicone, and 660 pmole/cm 3 biocompatible agent/cm 3 polymacon button. ANP-hyaluronate was added at 357 2 3 pmole/cm to silione and at 1655 pmole/cm to polymacon button material. The ANP derivatives coupled at higher load densities than the nBBA-Jeff on the hydrogel contact lens materials. These results were reversed for the silicone compound.
3, In Vitro Protein Adsorption Studies. Artificial human tears were prepared according to the formula found in B.P, Gloor, “The Lacrimal Apparatus” in Adler’s Physiology of the Eye: Clinical Applications (RA. Moses, CV. Mosby Co., St. Louis, MO (1981) the teachings of which are incorporated herein.
As indicated in that reference the major proteins present in human tears are serum albumin (HSA), gamma-globulin (HGG), and lysozyme (LYZ), The major sterols present in human tears are cholesterol and cholesterol esters, A. 3 H Proteins. The protein components were tritiated by reductive methylation with formaldehyde and tritiated sodium borohydride as described in N, Jentoft and D. C, Dearborn, Journal of Biochemistry, Vol, 254: 4359-4365 (1979) and incorporated herein by reference, Briefly, the biocompatible agent in Img/ml concentration in 0,1M HEPES, {i WO 88/02623 PCT/US87/02675 30 pH 7.’4 was methylated by formaldehyde reacting with tritiated sodium borohydride and rocking at 22 0 C for about 2 hours. The product was dialyzed against PBS in 0.01M phosphate, 0.15M sodium chloride, pH 7.4, and affinity purified on gelatin sepharose, Bound agent was eluted with 1M sodium bromide 0,02M sodium acetate, pH 5,0 then dialyzed against PBS, pH 7.4.
B. Preparation of Artificial Tears, The radiolabeled proteins described above were used in preparation of artificial tears, One of the radiolabeled proteins or the tritiated cholesterol was included in each tear mixture, The other components were not radiolabeled. The contact lens materials were incubated in the artificial tear solution for one week at 37 0 C with gentle agitation. At the end of this time the lens materials were washed with 5 x of 0,85% NaCl, The amount of protein adsorbed to the lens materials was then determined by liquid scintillation counting, In vitro protein deposition results are given in Table 5. Reduction in total protein deposition reached 85% in ANP-1000-OH modified Sofspin lenses.
Individual biocompatible agents increased or stayed at the same levels as some of the control contact lens materials, but the overall protein amounts were reduced for all lens materials except A-NP-1000-OH coated Polymacon buttons, ANP-4000-OH coated polymacon buttons and ANP-hyaluronate coated polymacon buttons.
These poor results were all obtained with virgin polymacon materials which appears to react differently than polymacon contact lenses, such as Sofspin lenses. Overall, these in vitro protein deposition studies demonstrated significant to dramatic decreases in protein deposition from artificial tears on various contact lens materials during a one week period.
i l- -Y~ Table 5: Iin Vitro PrOteis Adsorption Tears: 31, ProLeins* frumi Artificial Biocoumpatible AgeiiL ConLact MaLerial uglSA/ C11:2 f gZq of ugLys! of ug of Reduction control ugC11- control 2 control Total Protein control Total Protein Cotrols Polyviiiyl Chli oride Sol spill (1’olyulaconl) Periiaf I ex Vistamarc Lidofilcon Si 1 icone **Potymacon Buttois .1)25 Ioo-pp -524 .441 1 .49 1.,25 6 .978 5, 3 2.154 1121 3a.23 1.33 1.953 -343 1 .009 .272 6-983 .576 3.162 1.866 47.86 1.423 .264 4.797 48.76 4.586 1 .657 4 1.673 2.46 ANP-1000-011 Polyvinyl Clloride Sol Spin Pe riiaf I cx Vistamarc Lidofilcon Si liconie kp 0 lyiiiacoln Buttons .298 .241 ,582 -187 .640 .103 36-00 56-8 19.2 59.5 33.8 29.7 9.2 .696 .191 1-351 .378 -440 1-016 133 14.4 69.2 110.2 43.6 373-5 77.9 .0384i .04 1.693 39.19 1.73 -214 8.7 6.9 90.73 81.88 121 .5 81i. 1 1.032 .472 3.626 39.76 2.81 1-333 43.9] 69.3 14.93 75.6 81.5 61.3 80.41 105.4 30.7 85.07 24.4 18.5 38.8 19-6 111.0 5.!,4 2.117 100.0 ANP-4000 Polyvinyl Cloride Soflspin Vistaijia iec SilI icolie **PoIylaliI Bu~ttolis 430 1.16 -187 1.082 3Z-62 81-9 92.4 33-8 96._5 .356 .608 .686 -212 67-9 45.7 200.0 88.9 59.7 .1148 .297 1,3.24 .21:0 33.6 51.6 90.3 79. 5 .934 2.065 44 .11 1.534 43.655 62.7 65.3 90.5 92.6 lo. 7 37.3 34 7 116.1 4-172 1.863 75.1 x_ 1: Ri {)CiaIoktaLible Agent Contact Material ugIlSA!
CIU
of 1uy’lig d of ugLys] control cm control c11 2 ot ug of control Total Protein control RducLioll Total Protein nBBA-Je[ f Polyvillyl Chloride Sofspin Si] icone **Polymacou Buttons -632 .665 -978 26-35 120.3 52.9 87.2 .576 .859 061 109.9 64.5 22.4 .072 .531 .068 16.33 .922 41 1.28 2.055 1.107 26.37 85.9 64.9 66.8 63.28 14.1 35.1 33.2 36.72 81.76 .01 .14 .01 BBA-Jeff Polyvinyl Chloride Silicone **Po lymiacoii ButLtons ANP-Jtt Polyvinyl Chloride Silicone **PolymIaconk But tois .326 .921 30.61 62.1 .454 82.15 .089 94.9 3.695- 86.6 32.7 52.9 .290 66.7 .1.49 56 .4 1.07 1.159 34.32 71.8 69.9 82.34 28.2 30.1 17.66 .1A86 92.b .904 80.6 -231 87.0 83.7 80.5 .119i 43.5 -257 97.6 1.134 1.392 43.04 76.1 84.01 103.3 23.9 15.99 (3.3) 35.48 110-1 5.62 1.911 78.86 T hu values arte calCulated trom Polyntacon buttons are based on Values in pareatheses indicate 10 replicates volum~e rather than surtace area- cn 3 an inicrease in protein adsorption i WO8/0262323PC T/U S8’7/026 -33 The results of the in vitro cholesterol deposition studies are given in Table 6, The amount of cholesterol deposition after 7 days of incubation in artificial tears was reduced by as much as 83% on polyvinyl chloride, All contact lens types exhibited reduction of cholesterol deposition except the polymacon button pieces, Again, these materials react differently than the contact lenses made of the same polymer, 1 I WO 88/02623 PCT/US8/02675 34 Table 6: Cholesterol Adsorption from Artificial Tears: 3 H Cholesterol Biocompatible Agent Controls ANP-000 ANP -4000 nBBA-Jeff BBA-Jeff ANP-Jef if ANP Hyaluronate *ug CholeLiterol/ cm_ of Control Contact Material Polyvinyl Chloride ,ofspin Prmaflex Vis tamarc Lidofilcon Silicone Polymacon Button Polyvinyl Chloride Sofspin Permaflex Vistamarc Lidofilcon Silicone Polyrnacon Button Polyvinyl Chloride Sofspin Permaflex Vistamarc Silicone Polymacon Buttom Polyvinyl Chloride Sofspinl Permaflexc Silicone Polymacon Button Polyvinyl Chloride Silicone Potymacon Button Polyvinyl Chloride Silicone Polymacon Butt;on Reduction .096 .091 .196 .032 .053 .103 .215 ,026 .075 .134 .028 .046 086 .245 .0166 1101 4134 .023 .104 .248 ,038 .133 ,164 .072 ,148 .0214 107 .230 028 .224 .238 100 100 100 100 100 100 100 27,1 82.4 68,4 87.5 86.8 83.5 113.9 17.3 110.9 68.4 71.9 100.9 115.3 39.6 151.6 83. 7 69.9 68,8 22,3 D~ 3. 8 106,9 29.
217. 110.6 72.9 72.9 17.6 31.6 12,5 13.2Z1 16,5 82,7 (10.9) 31.6 28.1 (0-9) (15-3) 60,4 (51.6) 16.33 30. t 31.2 77.7 (318) (b.9) 70.2 Values were the averages of ten replicates, V ‘lues in parentheses indicate increase in cholesterol adsorption,
I
WO 88/02623 PCT/US87/02675 35 C, Amino Acid Analysis. Control and surface modified lenses were incubated in the artificial tear solution for one week at 37 0 C with gentle agitation. The lenses were washed with 5 10ml washes of 0,85% NaCl, then hydrolyzed with 6N HCI and the hydrolysates subjected to standard amino acid analyses on an amino acid analyzer, Total amino acid content of control and surface modified lenses were compared to each other. Reduction in total amino acid content indicated a reduction in protein absorption.
The total amino acid analyses of the acid hydrclyzed contact lenses are given in Table 8. These results are expressed as total amino acids in nmole/ml, These results again indicated that the ANP-1000-OH, ANP-4000-OH and nBBA-Jeff modifications of Sofspin polymacon lenses reduced the deposition-of proteins on the lenses after 7 days of incubation in artificial human tears, Table 7: Total Amino Acid Analyses from Artificial Tear Deposits on Contact Lenses Contact Biocompatible Total Amino Acids Material Agent nmol/lens no NH3- Reduction Sofspin ANP-1000 62.75 59.7 ANP-4000 136.272 12.4 nBBA-Jeff 105.381 32.3 Control 155.616 Permalens ANP-1000 168.714 32.5 ANP-4000 210.207 15.9 nBBA-Jeff 181.302 27,5 1 Control 249.939 4. In Vitro Toxicity Testinq, The biocompatible lens materials described above were tested for irritant or toxicity responses, Control and biocompatible lenses were prepared under sterile conditions with final washing procedures conducted in a laminar flow hood, The lenses were placed in a solution of a WO 88/02623 PCT/’US87/02675 36 known high glucose cell medium such as Dulbecco’s Modified Essential Medium, with 10% fetal calf ser’im, and 5% glutamine (to which antibiotic and anti-fungal agents had been added), Pieces of viable 3-5 month fetal bovine corneas were placed on top of the lenses. The epithelial surface of the cornea was placed in contact with the lens surface in some studies, and the endothelial cell surface was placed directly on the lens surface in other studies. The systems were placed in culture at 7-10% CO2 and 370C for 1-2 week periods. At various intervals after initiation of culture the viabilities of the epithelial and/or endothelial cells were assessed by staining procedures, In Vitro Assay for Stability of Covalent Bond, The stability of the covalent attachment was assessed by subjecting the surface-modified polymacon (polymethacrylate) to enzymatic cleaner (papain), thermal disinfection and chemical disinfection (buffered acqueous solution containing sodium chloride, sodiumborate and boric acid.) These results are given in Table 8.
Wb 88/02623 PCT/US87/02675 37 Table 8: Stability of Covalent Linkage to Cleaning Disinfection Procedures Biocompatible Agent ANP-1000 ANP-4000 nBBA-2000 BBA-2COO ANP- t Hyaluronate Treatment pmole/cm3 Remaining No treatment 831 100 Enzymatic cleaner 862 Boiling 761 91,1 Chemical cleaner 721 86.E No treatment 1574 100 Enzymatic cleaner 2012 100 Boiling 2092 100 Chemical cleaner 1564 99,4 No treatment 1732 100 Enzymatic cleaner 1785 100 Boiling 1795 100 Chemical cleaner 1129 65.2 No treatment 1651 100 Enzymatic cleaner 1996 100 Boiling 1619 98.1 Chemical cleaner 1409 85.3 No treatment 300 100 Enzymatic cleaner 317 100 Boiling 340 100 Chemical Cleaner 307 100 Values are the averages of 10 replicates ft- A WO 88/02623 WO 8802623PCT/US87/026i5 38 The covalent linkages remained 100% stable to enzymatic cleaning and thermal disinfection, There was some loss of biocompatible agent with the chemical disinfection procedures exccept for the ANP-hyaluronate.
6. In Vivo Assessment of Biocompatibility, Preliminary in vivo biocompatibility testing was conducted in rabbit model systems, A population of at least 24 animals was used in each study, Scieral lenses designo’d to fit rabbit eyes were used in these studies, The rabbits wore lenses according to the following schedule: 6 rabbits N1o lens left eye, control lens right eye 6 rabbits. control lens left eye; physically treated lens (same physical treatment as surface modif ied lenses, bu not coated with, biocompatible agent) right, eye 12 rabbits Control lens lo ft eye; Suire-ace-modlt’ied lens right eye, ‘*he rabbit$ were anesthotizod with Ketamine/ Xylalline prior to placing the lenses in the tabbit eyes, A methyl cellulcse/nocmal salikne wetting solution. was applied hc~arly to maintain adequate eye and lens lubrication, The oataots were worn hours!/ day. After chosen periods oE “Lens wear the-, rabbits were analyzed by slit lamp and flIuorescein dye mothod~ Th dereeof y itiat~on was. graded by the McDonald-Shadduck scale as described in, T. mc.Donald and J.A 1 Shadduck, “E”ye trritation,” in Advances in Modern To~icoloqyX, Vol. 4j pp, 162-166 (1977) incorporated herein by reference, The McDonald-Shadduck procedure allows the investigator to grade conjuotival WO 88/02623 PCT/US87/02675 39 congestion, conjuctival swelling, conjunctival discharge, aqueous flare, iris involvement and corneal cloudiness and other characters on a scale of 0-4, with 0 being normal and +4 the most complete involvement, The results of the in vivo rabbit studies are given in Table 9, The McDonald-Shadduck scores for the rabbits are represented in the table, Mann-Whitney U tests were performed on these results and indicated that there were no statistical differences between the surface-modified and control lenses (p 0.05), Therefore, these tests indicate that in this 4-day study in rabbits, no detectable differences in conjunctival congestion, conjunctival swelling, conjuntival discharge, aqueous flare, iris involvement, corneal cloudiness, pannus vascularization, norepithelial damage of the surface modified lenses was detected as compared to control lenses, The irritation which was demonstrated in the control and the modified lenses appeared to be associated with the tabbits’ development of tolerance to contact lenses.
Table 9: AVerage McDonald-Shadduck Scoes For :n Vivo Rabbit Study Day 1 Day 2 Day 3 Day 4 Control Lens 0.53 1 0.78 0.19 0.33 Surface I I Modiiied Lens 1 0.58 1 0.65 i 0.17 0.21 Example 3 Coupling of Albumin, Hepari n and U1okinase to Polyurethane Tubing 1, Preparation of Photolabel ed Albumin. Serum albumin (canine) was dissolved in 0.1M borate buffer at pH 9,0 A volume of 4-azido-2-nitrophenyl amino aproyl-N-oxysuccinimide (AP-EAC-NOS) solution ;1 i II o 88/02 2623 PCT/US87/0267 40 at 25 mg/ml in DMF to provide a 10 fold molar excess of ANP-EAC-NOS over albumin was added to the albumin with stirring at room temperature in the dark over about 12 hours using a syringe drive, The solution was then dialyzed in the dark against three one liter volumes of phosphate buffered saline (PBS), After dialysis, the solution was centrifugee to remove insoluble material, The absorance at 470 nm of a 1/100 dilution was measured spectrophotometrically to estimate the ANP/albumin ratio, 2. Photocoupling of Albumin to Polyurethane Tuhing, Polyurethane tubing was dipped into dioxane for thirty seconds after which it was immediately rinsed with deionized water, The etched tubing was immersed in a solution o photoreactive albumin for at least two hours at room temperature in the dark with mixing.
The tubing was then air dried for at least ten mintes in the dark, then exposed to high intensity visible light for at least one hour, The immersion in photoreactive albumin, drying and photolyzing was repeated twice, the last time the dipping was left overnight, The tubing was then washed in l,0 N NaCI for one hour at room temperature, The NaCl solution was changed at least once during the one hour, 3, Coupling of Hepa-in to lbumin on Polyurathann Tubing. The albumin-polyurethane tubing was immersed in 5,0 ml, of deionized water, 200 mg of l-ethyl-3- (3-dimethylaminopropyl) carbodimide (EDC) was dissolved in the water then the pH was adjusted to with 1N HCI. One ml of water containing 30 mg of heparin was added to the EDC solution, The pH was again adjusted to 4.0 with IN HC1, The solution containing the immersed polyurethane tubing was mixed for two hours at room temperature after which another 200 mg of EDC was added, The reaction was then allowed to WO 88/02623 PCT/US87/02675 41 continue overnight at room temperature. The tubing was then rinsed in PBS to remove uncoupled heparin and reaction biproducts, 4. Coupling of Urokinase to Albumin on Polyurethane Tubing. Polyurethane tubing having serum albumin immobilized thereon was immersed in 1,25% glutaraldehyde in 0.1M phosphate buffer, pH 7.0 for 15-18 hours at room temperature. The tubing was then washed in deionized water for 30 minutes, the water being changed at least once during that time. The polyurethane-albumin-glutaraldehyde was then immersed in a solution of urokinase (8.3 units/ml, 2-3 mg/ml) in 0,1M borate of pH 9.0 and mixed overnight at The tubing was then rinsed for four hours in PBS after which it was assayed for urokinase activity, Two polymers were used as the solid surface, polyurethane and polyhema. The modified surfaces yielded 1-10 mg heparin/cm 2 an 0,6-1,3 mg urokinase/ 2 cm Example 4 Coupling of a Film to a Solid Surface Formation of a Coating Film and its Covalent Attachment to a Surface, Preparation of ANP-hyaluronic acid, Photolabeled derivatives of hyaluronic acid (ANP-EAC-Jeffamine, BBA-Jeffamine and nitro- BBA-Jeffamine) were prepared as previously described, Films are formed from the photoreactive coating material .and placed on surfaces of contact lenses (by dipping and drying) in the dark, Covalent attachment to the biomaterial surface and strengthening of the film by intermolecular cross-linking may be accomplished through illumination.
11% A WO 88/02623 PCT/US87/02675 42 In another example, an artificial hip joint is soaked in ANP-EAC-Jeffamine-hyaluronic acid (,1:1 mg/ml) for three hours in the dark. The joint is then removed from solution and allowed to dry forming a thin film of coating material on the artificial joint, The film is then covalently attached to the joint by illumination at 400 to 450 nm for 8 hrs, at 4°C, The joint is then rinsed in physiological saline to remove uncoupled ANP-EAC-Jeffamine-hyaluronate.
The hyaluronic acid bound to the bone reduces friction and reduces wearing of the bone in the joint area, 100 mg of bovine serum albumin is dissolved in 2 ml of lM borate buffer pH 9. 14mg of ANP-AUD-NOS is dissolved in 50 ul of dimethylformamide (DMF). The ANP-AUD-NOS solution is added to the BSA solutiQ, slowly over 15 hrs at room temperature in the dark with good stirring. After an additional 3 to 4 hours of stirring the solution is dialyzed against ,1M borate buffer at pH 9 in the dark over 24 hrs, with at least 4 changes of 2 liters each of buffer. The dialyzed ANP-BSA is pipetted onto paraffin films in 00 ul aliquots and dried in the dark, After the films have dried they are overlaid with 100 ug aliquots of 1,25% glutaraldehyde and borate buffer pH 9 and incubated for one hour at room temperature in the dark, The films are then washed by slowly dropping water onto them ohile still on the paraffin films and allowing the water to run off. After one hour of such washing, the films are redried and then carefully lifr-ed off the paraffin film and transferred to a plastic surface polyurethane), On the plastic surface the films are again wetted with water containing 20% dioxane, then redried in the dark. The films on the plastic surfaces are then exposed to high i SWO 88/02623 43 PCT/US87/02675 intensity visible light for four hours at 4°C to bind the film to the surface with a fan blowing across the surface to prevent excessive heating of the surface.
While a preferred embodiment of the present invention has been described, it should be understood that various changes, adaptations and modifications may be made therein without departing from the spirit of the invention and the scope of the appended claims, r i

Claims (38)

1. A biocompatible device comprising a solid surface carrying molecules of a biocompatible agent, a chemical linking moiety residue covalently binding individual molecules of the biocompatible agent to the solid surface, the chemical linking moiety residue including a residue of a photochemically or thermochemically reactive group covalently bonded to the solid surface, and a residue of a different reactive group covalently bonded to molecules of the biocompatible agent, one of the groups being unresponsive to a stimulus to which the other group responds, the photochemically or thermochemically reactive group residue being bonded to the solid surface so that the individual molecules of the biocompatible agent are positioned sufficiently proximate to one another as to cause Q said molecules to effectively shield the solid surface and to provide a biocompatible effective surface.

2. A device as claimed in claim 1 wherein the biocompatible agent is a cell attachment factor.

3. A device as claimed in claim 2 wherein the cell attachment factor is laminin or fibronectin.

4. A device as claimed in claim 1 wherein the biocompatible agent is a growth factor. e**

5. A device as claimed in claim 4 wherein the growth factor is endothelial growth factor, epithilial growth factor, osteoblast growth factor, fibroblast growth factor, platelet derived growth factor, neural growth factor, or angiogenin growth factor. C-1/i ~II

6. A device as claimed in claim 1 wherein the biocompatible agent is an antimicrobial agent.

7. A device as claimed in claim 6 wherein the antimicrobial agent is lysosyme or penicillin.

8. A device as claimed in claim 1 wherein the biocompatible agent is a hydrophilic polymer.

9. A device as claimed in claim 8 wherein the hydrophilic polymer is polyethylene glycol, a hyaluronic acid, methyl cellulose, collagen or chitosan. A device as claimed in claim 1 or 8 wherein the biocompatible agent is collagen.

11. A device as claimed in claim 1 or 8 wherein the biocompatible agent is chitosan.

12. A device as claimed in claim 1 or 8 wherein the biocompatible agent is polyethylene glycol.

13. A device as claimed in claim 1 or 8 wherein the Sbiocompatible agent is a hyaluronic acid.

14. A device as claimed in claim 1 or 8 wherein the biocompatible agent is methyl cellulose. 0.0i 15. A device as claimed in claim 1 wherein the biocompatible agent is an antithrombogenic agent. 4- I ,%j f 46

16. A device as claimed in claim 1 wherein the biocompatible agent is albumin.

17. A device as claimed in claim 1 wherein the biocompatible agent is heparin.

18. A device as claimed in any one of claims 1 to 17 in the form of a contact lens or ophthalmic lens.

19. A device as claimed in any one of claims 1 to 17 in which said device comprises vascular graft tubing, dialysis tubing or membrane, blood oxygenator tubing or membrane, a blood bag, a catheter, a suture, a soft or hard tissue prosthesis, a synthetic prosthesis, an artificial organ, a contact lens or an intraocular lens.

20. A device as claimed in claim 18 wherein the biocompatible agent is a proteinase.

21. A device as claimed in claim 19 wherein the proteinase is papain.

22. A method of providing a biomaterial with a desired biocompatible surface, the method employing a solid surface of the biomaterial, molecules of a biocompatible agent joined to one another to form a biocompatible film, said e film carrying a chemical linking moiety having a residue of a reactive group covalently bonded to the film and a photochemically or thermochemically reactive group capable upon activation of covalently bonding to the solid surface, said method comprising: activating the photochemically or thermochemically reactive group to covalently bond the film to the solid surface. i S i. i~illil-l. .il?-i–li3~-..-~-ICII–il-.Vallll 47

23. A biocompatible device having a solid surface carrying molecules of a biocompatible agent joined to one another to form a biocompatible film, said film carrying a chemical linking moiety binding the film to the solid surface, the chemical linking moiety including the residue of a photochemically or thermochemically reactive group covalently bonded to the solid surface, and covalently bonded to the film of the biocompatible agent the residue of a different reactive group one of the reactive groups being unresponsive to a stimulus to which the other reactive group responds.

24. A device of any one of claims 1 to 18 wherein the solid surface is a polymeric substrate. A device of claim 19 wherein the polymeric substrate is polyurethane, polyvinylpyrrolidone, polyamide, t. polyamine, poly- tetrafluoroethylene, poly(p-phenyl- eneterepthalamide), polyvinyl chloride, polypropylene, polyacrylate, polymethacrylate, polyacrylamide, polyimine, polyester, polyethylene, cellulose, or silicone,

26. A method of providing a device with a desired biocompatible surface employing a solid surface of the device carrying molecules of a biocompatible agent, and a chemical linking moiety possessing a photochemically or thermochemically reactive group capable upon asctivation of covalently bonding to the solid surface, and possessing a different reactive group, capable of binding to the molecules of the biocompatible agent, one of the groups being unresponsive to a stimulus to which the other group responds, the method comprising: *1 L- i. j i ~e i 48 activating the different reactive group of the chemical linking moiety in the presence of the molecules of the biocompatible agent to cause the different reactive group to covalently bind the chemical linking moiety to the molecules; and activating the photochemically or thermochemically reactive group of the chemical linking moiety in the presence of a solid surface of the biomaterial to cause the photochemically or thermochemically reactive group to covalently bhnd to the solid surface and to bind the molecules to the solid surface in a sufficient population density of the molecules of the biocompatible agent to effectively shield the solid surface and to provide a biocompatible effective surface.

27. A method as claimed in claim 26 wherein the biocompatible agent is a cell attachment factor.

28. A method as claimed in claim 27 wherein the cell attachment factor is laminin or fibronectin,

29. A method as claimed in claim 26 wherein the Sbiocompatible agent is a growth factor.

30. A method as claimed in claim 29 wherein the growth factor is endothelial growth factor, epithilial growth factor, osteoblast growth factor, fibroblast growth factor, platelet derived growth factor, neural growth factor, or angiogenin growth factor.

31. A method as claimed in claim 26 wherein the biocompatible agent is an antimicrobial agent.

32. A method as claimed in claim 31 wherein the antimicrobial agent is lysosyme or penicillin. I 7\ *1 i. 49

33. A method as claimed in claim 26 wherein the biocompatible agent is a hydrophilic polymer.

34. A method as claimed in claim 33 wherein the hydrophilic polymer is polyethylene glycol, a hyaluronic acid, methyl cellulose, collagen or chitosan. A method as claimed in claim 26 or biocompatible agent is collagen.

36. A method as claimed in claim 26 or biocompatible agent is thitosan,

37. A method as claimed in claim 26 or biocompatible agent is polyethylene glycol.

38. A method as claimed in claim 26 or biocompatible agent is a hyaluronic acid.

39. A method as claimed in claim 26 or biocompatible agent is methyl cellulose. 33 wherein the 33 wherein the 33 wherein the 33 wherein the 33 wherein the 9 *9 .r 9* 9 .9 9* 99 9 A method as claimed in claim 26 wherein the biocompatible agent is an antithrombogenic agent.

41. A method as claimed in claim 26 wherein the biocompatible agent is albumin.

42. A method as claimed in claim 26 wherein the biocompatible agent is heparin. t- V ‘1 50

43. A method as claimed in any one of claims 26 to 42 wherein the device is a contact lens or ophthalmic lens. DATED this 8th day of July 1991. BIO-METRIC SYSTEMS, INC. WATERMARK PATENT TRADEMA4RK ATTORNEYS, 290 Burwood Road, HAWTHORN. VIC. 3122 AUSTRALIA 9 9* S 9 9* 9. .5 t4 9** 99** 9955 9 IAS:JZ(12.12) (CH) f- A

AU82320/87A
1986-10-17
1987-10-16
Improvement of the biocompatibility of solid surfaces

Ceased

AU615637B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US92056786A

1986-10-17
1986-10-17

US920567

1997-08-29

Publications (2)

Publication Number
Publication Date

AU8232087A

AU8232087A
(en)

1988-05-06

AU615637B2
true

AU615637B2
(en)

1991-10-10

Family
ID=25443967
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU82320/87A
Ceased

AU615637B2
(en)

1986-10-17
1987-10-16
Improvement of the biocompatibility of solid surfaces

Country Status (7)

Country
Link

EP
(1)

EP0326579B1
(en)

JP
(2)

JP2741378B2
(en)

AT
(1)

ATE116863T1
(en)

AU
(1)

AU615637B2
(en)

CA
(1)

CA1305068C
(en)

DE
(1)

DE3750989T2
(en)

WO
(1)

WO1988002623A1
(en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

CA1335721C
(en)

*

1987-12-24
1995-05-30
Patrick E. Guire
Biomolecule attached to a solid surface by means of a spacer and methods of attaching biomolecules to surfaces

US5182317A
(en)

*

1988-06-08
1993-01-26
Cardiopulmonics, Inc.
Multifunctional thrombo-resistant coatings and methods of manufacture

US5342693A
(en)

*

1988-06-08
1994-08-30
Cardiopulmonics, Inc.
Multifunctional thrombo-resistant coating and methods of manufacture

US5338770A
(en)

*

1988-06-08
1994-08-16
Cardiopulmonics, Inc.
Gas permeable thrombo-resistant coatings and methods of manufacture

US5262451A
(en)

*

1988-06-08
1993-11-16
Cardiopulmonics, Inc.
Multifunctional thrombo-resistant coatings and methods of manufacture

JP2855224B2
(en)

*

1988-07-22
1999-02-10
バイオ―メトリック システムズ，アイエヌシー．

Preparation of polymer surface

EP0649637A1
(en)

*

1988-08-24
1995-04-26
SLEPIAN, Marvin J.
Material for endoluminal paving and sealing

US5240747A
(en)

*

1989-05-11
1993-08-31
Kanegafuchi Kagaku Kogyo Kabushiki Kaisha
Process for modifying surfaces of materials

JP3056512B2
(en)

*

1990-08-02
2000-06-26
鐘淵化学工業株式会社

Material surface modification method

IL106922A
(en)

1992-09-14
1998-08-16
Novartis Ag
Composite materials with one or more wettable surfaces and process for their preparation

WO1995012420A1
(en)

*

1993-11-04
1995-05-11
Bsi Corporation
Barrier coatings for surfaces

US5585361A
(en)

*

1994-06-07
1996-12-17
Genzyme Corporation
Methods for the inhibition of platelet adherence and aggregation

DE4444445C2
(en)

*

1994-12-14
1998-07-02
Keller Ruprecht Priv Doz Dr Dr

Process for the production of tissue-compatible substrates, tissue-compatible substrate and its use

US5532311A
(en)

*

1995-02-01
1996-07-02
Minnesota Mining And Manufacturing Company
Process for modifying surfaces

US5583213A
(en)

*

1995-05-12
1996-12-10
Minnesota Mining And Manufacturing Company
Process to activate sulfated polysaccharides

US5674236A
(en)

*

1996-04-30
1997-10-07
Medtronic, Inc.
Lancet for capillary puncture blood samples

US5916585A
(en)

*

1996-06-03
1999-06-29
Gore Enterprise Holdings, Inc.
Materials and method for the immobilization of bioactive species onto biodegradable polymers

IL128941A
(en)

*

1996-09-13
2007-05-15
Advanced Medicine Res Inst
Ophthalmic composition containing a neurotrophic factor for treating an optic nerve functional disorder

US6197289B1
(en)

1997-07-01
2001-03-06
Terumo Cardiovascular Systems Corporation
Removal of biologically active agents

US6121027A
(en)

*

1997-08-15
2000-09-19
Surmodics, Inc.
Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups

US6054504A
(en)

*

1997-12-31
2000-04-25
Hydromer, Inc.
Biostatic coatings for the reduction and prevention of bacterial adhesion

US6465525B1
(en)

1998-03-18
2002-10-15
Surmodics, Inc.
Latent reactive blood compatible agents

US6835410B2
(en)

*

2001-05-21
2004-12-28
Novartis Ag
Bottle-brush type coatings with entangled hydrophilic polymer

US7348055B2
(en)

2001-12-21
2008-03-25
Surmodics, Inc.
Reagent and method for providing coatings on surfaces

US6968234B2
(en)

*

2002-04-25
2005-11-22
Medtronic, Inc.
Implantable medical device having biologically active polymeric casing

CA2497530C
(en)

2002-09-03
2011-04-12
Whatman Plc
Porous composite membrane and method for making the same

FR2903590B1
(en)

*

2006-07-13
2013-05-10
Commissariat Energie Atomique

CELL SENSING DEVICE BY CONTACT

US8932662B2
(en)

*

2006-12-15
2015-01-13
Coloplast A/S
Coatings prepared from poly(ethylene oxide) and photo-initator-containing scaffolds

WO2011131222A1
(en)

*

2010-04-19
2011-10-27
Invatec S.P.A.
Photoactivated polymeric material and its use for the preparation of medical devices

CN112316219B
(en)

*

2020-09-29
2022-05-10
浙江大学
Anti-adhesion hydrogel-silk scaffold composite membrane and preparation and application thereof

Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3959078A
(en)

*

1973-05-18
1976-05-25

Midwest Research Institute

Enzyme immobilization with a thermochemical-photochemical bifunctional agent

US4451568A
(en)

*

1981-07-13
1984-05-29

Battelle Memorial Institute

Composition for binding bioactive substances

Family Cites Families (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

JPS494559B1
(en)

*

1970-08-06
1974-02-01

JPS5538964B2
(en)

*

1972-05-16
1980-10-07

JPS5664788A
(en)

*

1979-10-27
1981-06-02
Unitika Ltd
Method for imparting enzyme activity to solid surface

EP0029411B1
(en)

*

1979-11-15
1984-05-30
Battelle Memorial Institute
Adhesive composition for depositing an adhesive coating able to fix biofunctional molecules, coating obtained and process for its preparation, substrate covered with the coating and its use as a biocatalyst

US4589881A
(en)

*

1982-08-04
1986-05-20
La Jolla Cancer Research Foundation
Polypeptide

US4526909A
(en)

*

1984-01-09
1985-07-02
Regents Of The University Of California
Polymethylmethacrylate delivery system for bone morphogenetic protein

IL76079A
(en)

*

1985-08-13
1991-03-10
Univ Ramot
Collagen implants

1987

1987-10-16
CA
CA000549485A
patent/CA1305068C/en
not_active
Expired – Lifetime

1987-10-16
JP
JP62506895A
patent/JP2741378B2/en
not_active
Expired – Lifetime

1987-10-16
EP
EP87907467A
patent/EP0326579B1/en
not_active
Expired – Lifetime

1987-10-16
DE
DE3750989T
patent/DE3750989T2/en
not_active
Expired – Lifetime

1987-10-16
AT
AT87907467T
patent/ATE116863T1/en
not_active
IP Right Cessation

1987-10-16
WO
PCT/US1987/002675
patent/WO1988002623A1/en
active
IP Right Grant

1987-10-16
AU
AU82320/87A
patent/AU615637B2/en
not_active
Ceased

1997

1997-09-11
JP
JP9287546A
patent/JP2981488B2/en
not_active
Expired – Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3959078A
(en)

*

1973-05-18
1976-05-25
Midwest Research Institute
Enzyme immobilization with a thermochemical-photochemical bifunctional agent

US4451568A
(en)

*

1981-07-13
1984-05-29
Battelle Memorial Institute
Composition for binding bioactive substances

Also Published As

Publication number
Publication date

CA1305068C
(en)

1992-07-14

EP0326579B1
(en)

1995-01-11

JP2741378B2
(en)

1998-04-15

JPH02500250A
(en)

1990-02-01

JPH10179726A
(en)

1998-07-07

EP0326579A1
(en)

1989-08-09

JP2981488B2
(en)

1999-11-22

AU8232087A
(en)

1988-05-06

DE3750989T2
(en)

1995-05-18

DE3750989D1
(en)

1995-02-23

WO1988002623A1
(en)

1988-04-21

EP0326579A4
(en)

1989-11-07

ATE116863T1
(en)

1995-01-15

Similar Documents

Publication
Publication Date
Title

AU615637B2
(en)

1991-10-10

Improvement of the biocompatibility of solid surfaces

US4979959A
(en)

1990-12-25

Biocompatible coating for solid surfaces

US5263992A
(en)

1993-11-23

Biocompatible device with covalently bonded biocompatible agent

US4973493A
(en)

1990-11-27

Method of improving the biocompatibility of solid surfaces

US5258041A
(en)

1993-11-02

Method of biomolecule attachment to hydrophobic surfaces

US5217492A
(en)

1993-06-08

Biomolecule attachment to hydrophobic surfaces

CA1335721C
(en)

1995-05-30

Biomolecule attached to a solid surface by means of a spacer and methods of attaching biomolecules to surfaces

Ratner et al.

1976

Synthetic hydrogels for biomedical applications

EP0494216B1
(en)

1997-05-14

Surfaces having desirable cell adhesive effects

US5945319A
(en)

1999-08-31

Periodate oxidative method for attachment of biomolecules to medical device surfaces

EP0425485B1
(en)

2000-10-04

Preparation of polymeric surfaces

US5741551A
(en)

1998-04-21

Preparation of polymeric surfaces

EP0608095B1
(en)

1999-05-06

Biomolecule attachment

US7122356B2
(en)

2006-10-17

Method for attachment of biomolecules to medical device surfaces

EP0803257B1
(en)

2003-10-01

Biomolecule attachment

US5002582A
(en)

1991-03-26

Preparation of polymeric surfaces via covalently attaching polymers

US5891506A
(en)

1999-04-06

Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices

US20080063627A1
(en)

2008-03-13

Tissue graft materials containing biocompatible agent and methods of making and using same

US20060193968A1
(en)

2006-08-31

Method for attachment of biomolecules to medical device surfaces

CA2212602A1
(en)

1998-02-09

Oxidative method for attachment of glycoproteins to surfaces of medical devices

CA1340345C
(en)

1999-01-26

Preparation of polymeric surfaces

Legal Events

Date
Code
Title
Description

2000-01-06
HB
Alteration of name in register

Free format text:
THE NAME OF THE PATENTEE(S) HAS BEEN CHANGED TO SURMODICS, INC.

Download PDF in English